Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals Inc (NY: AMRX )

5.060 +0.370 (+7.89%)
Official Closing Price Updated: 7:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amneal Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Recap: Amneal Pharmaceuticals Q1 Earnings
Amneal Pharmaceuticals (NYSE:AMRX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Amneal Reports First Quarter 2022 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Pharmaceuticals's Earnings Outlook
Amneal Pharmaceuticals (NYSE:AMRX) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
21 Stocks Moving in Monday's Pre-Market Session
Gainers Mullen Automotive, Inc. (NASDAQ: MULN) shares rose 16.2% to $2.51 in pre-market trading. Mullen Automotive announced plans to begin construction for EV battery pack... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Amneal Scores Second US Biosimilars Approval With Alymsys In Oncology
The FDA approved Amneal Pharmaceuticals Inc (NYSE: AMRX) Biologics License Application (BLA) for bevacizumab-maly, a biosimilar referencing Avastin. The product... 
Via Benzinga
Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report First Quarter 2022 Results on May 4, 2022
From Amneal Pharmaceuticals, Inc.
Via Business Wire
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with... 
Via Benzinga
Amneal to Present Results From the Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 at the 2022 American Academy of Neurology Annual Meeting
From Amneal Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Amneal Awarded Sub-License to Manufacture and Commercialize Generic Version of Co-Packaged Nirmatrelvir and Ritonavir in 95 Low- and Middle-Income Countries
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Pharmaceuticals's Return On Capital Employed Insights
Amneal Pharmaceuticals (NYSE:AMRX) brought in sales totaling $536.90 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 235.83%, resulting... 
Via Benzinga
Amneal Pharma's Q4 Earnings Fall Short Of Expectations, Sees FY22 Sales Growth Of 7%
Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q4 revenue of $537 million, an increase of 5% Y/Y, marginally missing the consensus of $537.35 million. The increase was... 
Via Benzinga
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label... 
Via Benzinga
Recap: Amneal Pharmaceuticals Q4 Earnings
Amneal Pharmaceuticals (NYSE:AMRX) reported its Q4 earnings results on Wednesday, March 2, 2022 at 06:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Amneal Pharmaceuticals's Earnings: A Preview
Amneal Pharmaceuticals (NYSE:AMRX) is set to give its latest quarterly earnings report on Wednesday, 2022-03-02. Here's what investors need to know before the announcement.... 
Via Benzinga
Earnings Scheduled For March 2, 2022
Companies Reporting Before The Bell • SIGNA Sports United (NYSE:SSU) is expected to report quarterly loss at $0.04 per share on revenue of $283.61 million. •... 
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
Amneal Expands Injectables Portfolio with 4 New Products
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report Fourth Quarter and Full Year 2021 Results on March 2, 2022
From Amneal Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Annexon Announces Mixed Phase 2 Data From Huntington Disease Trial Annexon,... 
Via Benzinga
Amneal's $83M Saol Acquisition Deal Expands Its Neurology Presence Into Spasticity
Amneal Pharmaceuticals Inc (NYSE: AMRX) has agreed to acquire Saol's Baclofen franchise, including Lioresal, Lyvispah, and a pipeline product under development for $... 
Via Benzinga
Amneal Acquires Saol Therapeutics’ Baclofen Franchise
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Virtually Participate at the 40th Annual J.P. Morgan Healthcare Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers GBS (NASDAQ:GBS 
Via Benzinga
TherapeuticsMD, Amneal Settle US Patent Litigation For Bijuva
TherapeuticsMD Inc (NASDAQ: TXMD) has settled the previously disclosed U.S. patent litigation for Bijuva with Amneal Pharmaceuticals Inc (NYSE: AMRX).... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.